Member
Perfusion Medical
Perfusion Medical is dedicated to commercializing PEG-20k, a revolutionary drug designed to treat hemorrhagic shock and other ischemic conditions. With over $18 million in funding from the Department of Defense and numerous studies supporting its efficacy, the company aims to improve patient outcomes significantly.
Industries
N/A
Nr. of Employees
small (1-50)
Perfusion Medical
12110 Sunset Hills Rd Suite 600, Reston, VA 20190, USA; 800 East Leigh Street, Richmond, VA 23219, USA
Products
Investigational high-molecular-weight polyethylene glycol intravenous resuscitation solution (investigational)
An investigational intravenous solution formulated with high-molecular-weight polyethylene glycol intended to reduce ischemic tissue swelling, decompress capillaries, restore microcirculatory perfusion, and improve oxygen delivery in hemorrhagic shock and other ischemic conditions.
Investigational high-molecular-weight polyethylene glycol intravenous resuscitation solution (investigational)
An investigational intravenous solution formulated with high-molecular-weight polyethylene glycol intended to reduce ischemic tissue swelling, decompress capillaries, restore microcirculatory perfusion, and improve oxygen delivery in hemorrhagic shock and other ischemic conditions.
Expertise Areas
- Trauma resuscitation therapeutics
- Preclinical large-animal efficacy studies
- Intravenous formulation and CMC development
- Regulatory strategy for investigational IV therapeutics
Key Technologies
- High-molecular-weight polyethylene glycol IV formulations
- Large-animal hemorrhagic shock models (swine, rodent)
- Osmotic-gradient-based tissue decompression mechanism
- Physiological monitoring of perfusion and coronary perfusion pressure